Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Silence Therapeutics (SLN) EBITDA Margin: 2020-2025

Historic EBITDA Margin for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to -16,505.66%.

  • Silence Therapeutics' EBITDA Margin fell 1450319.00% to -16,505.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -321.21%, marking a year-over-year increase of 4512.00%. This contributed to the annual value of -146.38% for FY2024, which is 5709.00% up from last year.
  • Per Silence Therapeutics' latest filing, its EBITDA Margin stood at -16,505.66% for Q3 2025, which was down 54.29% from -10,697.77% recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' EBITDA Margin peaked at -17.20% during Q4 2024, and registered a low of -20,006.34% during Q1 2025.
  • Over the past 3 years, Silence Therapeutics' median EBITDA Margin value was -633.59% (recorded in 2023), while the average stood at -4,868.51%.
  • Per our database at Business Quant, Silence Therapeutics' EBITDA Margin spiked by 61,639bps in 2024 and then crashed by 1,997,079bps in 2025.
  • Over the past 5 years, Silence Therapeutics' EBITDA Margin (Quarterly) stood at -329.91% in 2021, then soared by 9,987bps to -230.03% in 2022, then tumbled by 40,356bps to -633.59% in 2023, then surged by 61,639bps to -17.20% in 2024, then slumped by 1,450,319bps to -16,505.66% in 2025.
  • Its last three reported values are -16,505.66% in Q3 2025, -10,697.77% for Q2 2025, and -20,006.34% during Q1 2025.